Chemotherapy Complications
Not every bad result associated with cancer chemotherapy is caused by negligent care. Mediports and similar devices have a simple structure, but one that can fail without warning.
Complications associated with chemotherapy can raise complex questions involving standards of care, medication toxicity, infusion device failure, treatment response, and causation. Not every severe or unexpected outcome associated with cancer treatment is the result of negligent care, and careful medical analysis is often required to determine the underlying cause of injury.
For example, a patient receiving Adriamycin through a venous access device may develop severe tissue injury if chemotherapy leaks into surrounding soft tissue, a complication known as extravasation. In some cases, the cause may involve improper needle placement or damage to the device during treatment. In others, the infusion device itself may fail because of catheter separation, leakage, or rupture of the device septum. These failures can occur without warning and may not become apparent until significant tissue injury has already occurred.
When such cases arise, preservation and examination of the device after removal can be critically important in determining whether the injury resulted from device failure, improper handling, or another cause. Because treatment options after significant chemotherapy extravasation are limited, the resulting damage can be severe despite appropriate subsequent care.
Other complications involve unusual or unpredictable drug toxicity. For example, a small percentage of patients lack an enzyme known as DPD, which is essential for proper metabolism of the chemotherapy drug 5-fluorouracil (5FU). Patients with DPD deficiency may develop life-threatening toxicity after receiving standard doses of treatment, including severe diarrhea, abdominal pain, shock, and death.
Although laboratory testing for DPD deficiency exists, routine screening has not traditionally been considered standard practice because the condition is rare and severe toxicity can occasionally occur even in patients with normal enzyme levels. In these cases, analysis often centers not only on whether testing was performed, but also on how early signs of toxicity were recognized, evaluated, and managed by the treating physician.